Hoogendijk et al., 1995
GLP-1RA therapy, when prolonged and potent, may lead to a form of iatrogenic ERM : Short-term gains: lower glucose, lower weight, lower cardiovascular risk Long-term risks: impaired amino-acid balance, reduced re-anabolism, muscle loss, frailty, diminished resilience This progression can be subtle and clinically silentbiochemically detectable long before symptoms appear
The positive relationships between oxidative stress markers and apoptosis reinforce the contribution of oxidative stress in the perturbation of apoptosis in SLE [8,9]
Takes ~5 minutes HIPAA-secure intake Cancel anytime Compounded GLP-1 & GIP therapy leverages GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) working synergistically to enhance insulin secretion, reduce appetite, and promote fullness
The catch is that the same microgram dose is a different number of units at every concentration
The mechanism of action of PT-141 is independent of nitric oxide signaling pathways and peripheral vascular mechanisms, offering an alternative treatment modality for these patients
